Asthma as a hidden disease in rural China: opportunities and challenges of standard case management

Kan, X H; Chiang, Chifa; Enarson, Donald A.; Rao, H L; Chen, Q.; Aït-Khaled, N; Chen, G. W.

doi:10.5588/pha.12.0025

Cited by 15 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may reflect an ongoing misunderstanding among some policy-makers, specialist physicians, and other health workers about the importance of ICS in the long-term management of asthma. The lack of prioritisation of ICS in national level lists is likely to be playing a role in the underprescription and underuse of ICS which continues to be reported [32,33,34].…”

Section: Discussionmentioning

confidence: 99%

Essential Medicines at the National Level: The Global Asthma Network’s Essential Asthma Medicines Survey 2014

Bissell

Ellwood

et al. 2019

IJERPH

View full text Add to dashboard Cite

Patients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low- and middle-income countries (LMICs) is limited. The World Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013–2020 sets an 80% target for essential NCD medicines’ availability. Poor access is partly due to medicines not being included on the national Essential Medicines Lists (EML) and/or National Reimbursement Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how many countries have essential asthma medicines on their EML and NRL, which essential asthma medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013–2015 of Global Asthma Network principal investigators generated 111/120 (93%) responses—41 high-income countries and territories (HICs); 70 LMICs. Patients in HICs with NRL are best served (91% HICs included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34%) LMICs with no NRL and the 14 (30%) LMICs with an NRL, however no ICS are likely to have very poor access to affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML or NRL. Technical guidance and advocacy for policy change is required. Improving access to these medicines will improve the health system’s capacity to address NCDs.

show abstract

Section: Discussionmentioning

confidence: 99%

Essential Medicines at the National Level: The Global Asthma Network’s Essential Asthma Medicines Survey 2014

Bissell

Ellwood

et al. 2019

IJERPH

View full text Add to dashboard Cite

show abstract

“…9,10 A situation analysis was performed to evaluate asthma management practice in China. 11 Asthma was found to be a hidden disease in Huaiyuan County, Anhui Province, where asthma was commonly diag-…”

Section: Resultsmentioning

confidence: 99%

Management of asthma in Benin: the challenge of loss to follow-up

Adé

Gninafon

Tawo

et al. 2013

public health action

Self Cite

View full text Add to dashboard Cite

“…The Union implemented asthma pilot projects in Benin [11], China (Huaiyuan County) [12], El Salvador [13] and Sudan [14]. These projects found that inhaled corticosteroids were not available in any of these sites in the public sector and that asthma was greatly underdiagnosed.…”

Section: Introductionmentioning

confidence: 99%

“…GAN Phase I is a development from ISAAC ( particularly Phases One [17][18][19][20][21] and Three [22][23][24]), and The Union [11,12,14,25]. GAN Phase I has extended its surveillance to include adults, for whom there are limited global data, and to assess asthma management, which is commonly suboptimal in settings with limited access to quality-assured essential asthma medicines.…”

Section: Introductionmentioning

confidence: 99%

The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors

Ellwood

Asher

Ne³

et al. 2016

Eur Respir J

129

136

View full text Add to dashboard Cite

The Global Asthma Network (GAN), established in 2012, followed the International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700 000 adolescents and children from 156 centres in 56 countries; it found marked worldwide variation in symptom prevalence of asthma, rhinitis and eczema that was not explained by the current understanding of these diseases; ISAAC Phase Three involved over 1 187 496 adolescents and children (237 centres in 98 countries). It found that asthma symptom prevalence was increasing in many locations especially in low- and middle-income countries where severity was also high, and identified several environmental factors that required further investigation.GAN Phase I, described in this article, builds on the ISAAC findings by collecting further information on asthma, rhinitis and eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital admissions, management and use of asthma essential medicines. The subjects will be the same age groups as ISAAC, and their parents. In this first global monitoring of asthma in children and adults since 2003, further evidence will be obtained to understand asthma, management practices and risk factors, leading to further recognition that asthma is an important non-communicable disease and to reduce its global burden.

show abstract

Asthma as a hidden disease in rural China: opportunities and challenges of standard case management

Cited by 15 publications

References 9 publications

Essential Medicines at the National Level: The Global Asthma Network’s Essential Asthma Medicines Survey 2014

Essential Medicines at the National Level: The Global Asthma Network’s Essential Asthma Medicines Survey 2014

Management of asthma in Benin: the challenge of loss to follow-up

The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors

Contact Info

Product

Resources

About